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Liver transplantationa b s t r a c t
Introduction: Hepatitis D Virus (HDV) infection is vanishing in Italy. It is therefore believed that hepatitis
D is no longer a medical problem in the domestic population of the country but remains of concern only
in migrants from HDV-endemic areas.
Objectives: To report the clinical features and the medical impact of the residual domestic HDV infections
in Italy.
Methods: From 2010 to 2019, one hundred ninety-three first-time patients with chronic HDV liver dis-
ease attended gastroenterology units in Torino and San Giovanni Rotondo (Apulia); 121 were native
Italians and 72 were immigrants born abroad. For this study, we considered the 121 native Italians in
order to determine their clinical features and the impact of HDV disease in liver transplant programs.
Results: At the last observation the median age of the 121 native Italians was 58 years. At the end of the
follow-up, the median liver stiffness was 12.0 kPa (95% CI 11.2–17.4), 86 patients (71.1%) had a diagnosis
of cirrhosis; 80 patients (66.1%) remained HDV viremic. The ratio of HDV to total HBsAg transplants
Gian Paolo Caviglia, S. Martini, A. Ciancio et al. Journal of Advanced Research 33 (2021) 183–187varied from 38.5% (139/361) in 2000–2009 to 50.2% (130/259) in 2010–2019, indicating a disproportion-
ate role of hepatitis D in liver transplants compared to the minor prevalence of HDV infections in the cur-
rent scenario of HBsAg-positive liver disorders in Italy.
Conclusion: Though HDV is vanishing in Italy, a legacy of ageing native-Italian patients with advanced
HDV liver disease still represents an important medical issue and maintains an impact on liver
transplantation.
 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Since the discovery of the Hepatitis D Virus (HDV) in the 1970 s,
the prevalence of this infection and the medical impact of hepatitis
D have much diminished in the Western World [1]. Critical to the
control of the infection was the implementation of vaccination
against the Hepatitis B Virus (HBV), which has led to the depletion
of carriers of the hepatitis B surface antigen (HBsAg) necessary for
the HDV to disseminate.
Italy has been central to the monitoring of the epidemiology of
HDV infection throughout the last four decades [2–4]. The country
was the first among industrialized countries to introduce in 1991
universal HBV vaccination for neonates and 12-years-old adoles-
cents [5]; by 2020, almost all 40 years old Italians are protected
from the HBV and by default from hepatitis D.
The prevalence of the antibody to the HDV (anti-HD) in HBsAg
carriers with liver disease diminished in Italy from 24.6% in 1983
to 8.15% at the end of the last century [6,7]. It has then remained
stable due to the input of new infections brought into the country
by HDV-infected immigrants; among 786 HBsAg carriers collected
in 2019, the overall prevalence of anti-HD was 9.9% and it was 6.4%
in Italian-natives and 26.4% in immigrants [8].
We report in this study the clinical features and current medical
impact of the residual population of native HDV-infected Italians.Patients and methods
Study population
A total of 193 patients with chronic HDV infection were newly
referred from 2010 to 2019 to the Gastroenterology Units of the
University of Torino and of the Ospedale Casa Sollievo Sofferenza
- IRCCS of San Giovanni Rotondo (SGR), in Northern and Southern
Italy; 121 of the patients were born in Italy (native-Italians) and
72 were born abroad and immigrated to Italy. For the purpose of
this study we considered only the 121 native-Italian patients.
All the 121 patients were HBsAg and anti-HD seropositive, and
had a chronic liver disease diagnosed by clinical and biochemical
evaluation and/or by liver elastography (FibroScan, EchosensTM,
Paris, France). Their medical histories were reviewed and the med-
ical/virological features and clinical course from presentation to
the last follow-up time were determined and compared through-
out a median follow-up of 8 year (range 1–9) during which they
were submitted to several visits with collection of serum samples
at each visit.
In addition, we analyzed data from 269 HDV liver transplants
performed from 2000 to 2019 at the Liver Transplant Unit of Torino
which is a national referral center for HDV transplantation; the
demographic features, the ratio of HDV to HBV transplants and
the reasons for transplantation were retrieved from the Torino
Liver Transplant Registry.184Ethics statement
All the patients signed an informed consent to allow access to
medical data, collected for research projects and which were
approved by the ethic committees in the participating centers
(Comitato Etico Interaziendale A.O.U. Città della Salute e della
Scienza di Torino - A.O. Ordine Mauriziano - A.S.L. Città di Torino,
approval no. CEI-690 and Comitato Etico Casa Sollievo della Sof-
ferenza, approval no. 50/CE). All the procedures described in the
present work were carried out according to the principles of the
Declaration of Helsinki.
Serology and virology
The ARCHITECT-QT assay (Abbott Diagnostics, Abbott Park, IL,
USA) was used for the determination of human serum HBsAg [9].
HBV DNA was detected and quantified in plasma with the
COBAS/AmpliPrepCOBAS TaqMan HBV test, version 2.0 (Roche
Molecular Diagnostics, Branchburg, NJ, USA) [10]. Total, predomi-
nantly IgG anti-HD were assessed by ETI-AB-DELTAK-2 enzyme
immunoassay and IgM anti-HD by ETI-DELTA-IGMK-2 (DiaSorin,
Saluggia, Italy). HDV RNA was detected by Real Time quantitative
PCR (RT-qPCR) as previously described [11]. The assay was cali-
brated in International Units against the 1st WHO International
Standard for HDV RNA [12]; it showed a linearity of quantification
ranging from 2  102 to 2  109 IU/ml and a sensitivity of 293 IU/
ml. The HDV genotype was determined by direct sequencing
(BMR-GENOMICS, Padova, Italy) and multiple alignements using
CLUSTAL-X software with the reference sequences of the eight
HDV genotypes retrieved from GenBank.
Statistical analysis
Data distribution was checked by D’Agostino-Pearson normality
test. Pairwise comparison of continuous variables was performed
by Wilcoxon test while categorical data were compared by McNe-
mar test or chi-squared test where appropriate. Fisher’s exact test
or Mann-Whitney test were used to compare data from indepen-
dent groups. For all analyses, a P < 0.05 was considered statistically
significant. Statistical analysis was performed using MedCalc soft-
ware version 18.9 (MedCalc bvba, Ostend, Belgium).
Results
HDV patients recruited from 2010 to 2019
Demographic features and risk factors
The median age at presentation and at the end of the follow-up
was 50 (32–71) and 58 (41–77) years respectively; the age distri-
bution of the patients at the end of the follow-up is shown in
Fig. 1. The male to female ratio was 83/38. The median body mass
index was 25.0 (18.7–38.6) Kg/m2. Thirtheen patients were obese
(BMI  30 Kg/m2); 8 patients (6.6%) admitted abuse of alcohol.
Only four patient had type 2 diabetes requiring therapy. Risk fac-
tors for HDV infection could be identified in 57 patients (47.1%);
Fig. 1. Age distribution of the 121 native-Italians patients at the last follow-up.
Table 1







Serologic and virologic parameters
Anti-HD IgM positive, n (%) 74 (61.2%) 46 (38.0%) <0.001b
HBsAg positive, n (%) 121 (100%) 112
(92.6%)
0.003b
HDV RNA positive, n (%) 112 (92.6%) 80 (66.1%) <0.001b
HDV RNA positive (<2000 IU/mL), n
(%)
16 (14.3%) 18 (22.5%)
HDV RNA positive (2000–100000 IU/
mL), n (%)
24 (21.4%) 26 (32.5%) <0.001c
HDV RNA positive (>100000 IU/mL),
n (%)
72 (64.3%) 36 (45.0%)
HBV DNA positive, n (%) 107 (88.4%) 67 (55.4%) <0.001b
Biochemical parameters
ALT (U/L), median (range) 76 (14–410) 49 (13–
565)
0.002d
AST (U/L), median (range) 64 (20–186) 48 (12–
248)
0.026d























Cirrhosis, n (%) 65 (53.7%) 86 (71.1%) <0.001b
Ascites, n (%) 0 (0%) 31 (25.6%) <0.001b
Abbreviations: ALT, alanine aminotransferase; anti-HD, antibodies to the HDV; AST,
aspartate aminotransferase; CI, confidence interval; HBsAg, hepatitis B surface
antigen; HBV, hepatitis B virus; HDV, hepatitis D virus; INR, international normal-
ized ratio; N, number
a performed in 83 patients (68.6%).
b calculated by McNemar test.
c calculated by chi-squared test.
d calculated by Wilcoxon test.
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15 patients (26.3%) reported intravenous drug abuse or mercenary
sex.
Virologic and biochemical features
At recruitment, 112 (92.6%) patients were HDV-RNA seroposi-
tive; 9 patients were HDV RNA seronegative, but previous labora-
tory records documented that they had been previously HDV
RNA positive. The genotype of HDV, determined in 25 patients,
was genotype 1 in all. All the patients remained positive for anti-
HD throughout the follow-up. None was or became positive for
antibodies to the human immunodeficiency virus. Eight patients
were positive for antibodies against the Hepatitis C Virus; none
was positive for serum HCV RNA, five had previously eradicated
the virus with specific antiviral treatments. The virologic, biochem-
ical and clinical features at first observation and last observation
are shown in Table 1.
From the first observation to the end of the follow-up, 28 out of
74 patients (37.8%) lost IgM antibodies to HDV and 9 (7.4%)
became HBsAg seronegative. Among viremic patients, the median
serum HDV RNA decreased from 268250 IU/mL (95% CI 114508–
1137672) to 81900 IU/mL (95% CI 33383–149683) (P < 0.001); 32
of 112 (28.6%) became HDV RNA negative. The percentage of the
patients with HDV RNA positive below 2000 IU/mL and between
2000 and 100000 IU/mL increased by 8.2% and 11.1%, respectively,
while the percentage of patients with HDV RNA above 100000 IU/
mL decreased by 19.5%. The number of HBV DNA positive patients
diminished from 107 (88.4%) to 67 (55.4%), with a median value
HBV DNA of 40 IU/mL (95% CI 22–94) at the last observation.
Clinical features
A past diagnosis of severe active hepatitis or cirrhosis was
recorded in 93 patients (76.9%) The other 28 patients (23.1%) had
been symptom-free and they were either unaware until recently
of a viral liver disease or reported a past diagnosis of only minor
and apparently irrelevant liver alterations; there were 7 patients
belonging to a subgroup of 13 who had a histological diagnosis
of mild chronic hepatitis D (CHD) (Ishak score: staging  2, grad-
ing  3) made in Torino in the 1980–1990 s [3]; as their liver tests
remained normal or borderline for up to 8 years of follow-up, they
had been dismissed from further surveillance [3].
At presentation to this study, the median liver stiffness of the
patients was 11.0 kPa (95% CI 7.0–12.5); a cirrhosis had been diag-
nosed by histology in 13 of 36 (29.8%) patients who underwent a185liver biopsy, and by liver stiffness (12.5 kPa) or clinical features
(i.e. nodular hepatomegaly, splenomegaly) in 52 other patients.
Throughout the follow-up, the median value of alanine amino-
transferase (ALT), aspartate aminotransferase (AST), platelet count
and albumin diminished significantly; the INR did not change.
Thirty-two patients (26.4%) underwent nucleos(t)ide analogues
treatment to prevent possible recrudescence of hepatitis B. Nine-
teen patients (15.7%) were treated with Peg-IFN; nine attained a
sustained response, five lost the HBsAg. In four patients, the HBsAg
cleared spontaneously from serum. Other 23 patients became
spontaneously HDV RNA negative during the follow-up; 11 had
been previously given IFN-based treatment without achieving viral
eradication.
At the last follow-up observation, the median liver stiffness
value was 12.0 kPa (95% CI 11.2–17.4). Thirty-one (25.6%) patients
developed ascites and 20 (16.5%) a hepatocellular carcinoma
(HCC). Eleven died; 27 (22.3%) underwent liver transplantation,
13 (48.1%) for HCC and 14 (51.9%) for liver failure.
HDV liver transplants from 2000 to 2019
One thousand three hundreds ninety-one and 1255 liver trans-
plants were performed in Torino in the decade 2000–2009 and
2010–2019 respectively, of which 361 (25.9%) and 259 (19.0%) in
HBsAg carriers; 139 (38.7%) and 130 (50.2%) of the HBsAg-
positive patients were coinfected with the HDV. The demographic
and clinical data are reported in Table 2. The 269 HDV-positive
recipients were significantly younger than the 351 HBV monoin-
fected recipients (51.1 [50.0–52.7] years vs. 56.4 [55.7–57.1];
Table 2
HDV and HBV transplants performed in Torino from 2000 to 2019.
2000–2009 2010–2019
Overall HDV positive HBV monoinfected Overall HDV positive HBV monoinfected
LT, N (%) 361 139 (38.5%) 222 (61.5%) 259 130 (50.2%) 129 (49.8%)
Age (years), median (95% CI) 52.8 (51.9–54.1) 48.6 (46.6–50.7) 55.3 (54.2–56.1) 56.7 (55.6–57.2) 54.3 (52.3–55.7) 58.0 (57.1–59.8)
Gender, M/F 303/58 102/37 201/21 211/48 95/35 116/13
Indication for transplantation:
HCC 29/139 (20.9%) 121/222 (54.5%) 49/130 (37.7%) 91/129 (70.5%)
Liver failure 110/139 (79.1%) 101/222 (45.5%) 81/130 (62.3%) 38/129 (29.5%)
Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; N, number; M/F, male to female ratio; LT, liver transplantation.
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(139/361) in 2000–2009, and 50.2% (130/259) in 2010–2019
(P = 0.004). The prevalent indication for transplantation was liver
failure in the HDV coinfected patients (191/269; 71.0%) and HCC
in the HBV monoinfected (212/351; 60.3%) (P < 0.001) (Table 2).
Discussion
This is the last of four surveys [2–4] which reported the natural
history of HDV infection as it unfolded in Italy from the discovery
of the virus in the late 1970 s to the present time. From the first
report in 1983 [2] to the second in 1999 [3] the perception of
CHD changed from a severe disease frequently predisposing to
liver failure to a picture including also minor liver disorder, and
in the third report in 2010 [4] the mean age of the patients and
the prevalence of cirrhosis had significantly increased.
Now and then, the patients were collected in the same reference
gastroenterology units in Torino and Apulia but in the meanwhile
the diagnostic methodology has changed; in the previous series the
diagnosis was based on a liver biopsy but in the present series it
was based primarily on positive HDV serology and abnormal liver
elastography.
In keeping with the epidemiologic demise of the HDV among
native Italians, we have not observed new and fresh forms of
CHD but only advanced liver diseases. The infection is outliving
in ageing patients, whose disease is diminishing in viral and
inflammatory activity; at the end of the follow-up their median
age was 58 years, i.e. 8 years older than the patients recruited in
the 1991–2005 survey [4], and the median ALT level, the rate of
IgM anti-HD-positivity and the percentage of viremic patients
had consistently diminished. Though one fourth of the patients
cleared serum HDV-RNA and 7.4% cleared the HBsAg, 71.4% of
the 80 patients who remained viremic maintained a consistent
titer of serum HDV RNA, with a median of 81900 IU/mL. The
changes in HD viremia were mostly spontaneous; only 9 of the
19 patients treated with Peg-IFN in this study lost the HDV RNA
and 5 of them lost also the HBsAg.
Many patients had already accumulated important liver scar-
ring at recruitment into the present survey and the liver fibrosis
has further advanced during the follow-up to a median liver stiff-
ness of 12.0 kPa; in comparison with the patients recruited in
the 1991–2005 survey [4], the proportion with overt cirrhosis
had increased from 56.4% to 71.1% and the percentage with HD vir-
emia had diminished from 71.8% to 66.1%.
The disease was complicated by ascites and/or by an HCC in 44
(36.4%) patients while the clinical course was apparently unevent-
ful in 63.6%; however, during the follow-up the median serum
albumin concentration and blood platelets count diminished sig-
nificantly also in the latter, indicating that portal hypertension
had developed in many.
The long-term survival of cirrhotic patients with the HDVwould
seem surprising, as this virus causes the most severe form of
chronic viral hepatitis [13]. This was previously explained by a186peculiar biphasic course of CHD; though in many patients CHD
rapidly progressed to cirrhosis within a few years with a steep
decrease in survival curves, in patients who outlived the disease
abated, consenting a normal existence for decades [3]. Surprisingly,
however, we found that cirrhosis had developed insidiously also in
23% of the patients of this survey who did not report a previous
history of significant liver damage, suggesting that advanced
HDV disease may result not only from burnt-out cirrhosis but also
from an originally unassuming liver injury that progressed slowly
over decades; by reason of their long natural history and survival
advantage minor but insidiously progressive CHDs accumulating
over time are likely to contribute an important share to the current
scenario of HDV cirrhotics. The issue is of clinical relevance; in
common practice, testing for HDV is often neglected in minor
forms of chronic HBsAg liver disease on the belief that HDV is asso-
ciated only with serious liver disease [14]. However the recogni-
tion that also these forms of are prone to evolve if related to the
HDV, requires that reflex testing for anti-HD is performed in all
cases of HBsAg patients; this becomes more compelling with the
perspective of new therapies that promise to control hepatitis D
over the long-term [15].
A perception of the residual medical burden of HDV comes also
from liver transplantation registries. The number of HDV trans-
plants performed in the decade 2010–2019 in Torino and the ratio
of HDV to HBV transplants did not diminish compared to the pre-
vious decade, pointing to a disproportionate number of HDV trans-
plants versus the minor epidemiologic weight of the infection in
the contemporary HBsAg scenario [16].
The same is true from the European Liver Transplant registry.
Though the residual prevalence of the HDV in the continent is
much lower than the HBV, in the last 15 years the percentage of
HBsAg/HDV to total HBsAg transplants amounted to 27% with a
2% increase from the 25% ratio of the previous decade [17]. The
paradox may be explained by the different impact of therapy in
chronic hepatitis B (CHB) and in CHD. While the only therapy avail-
able for CHD remains the time-honored but low-performing alfa
Interferon that failed to control HDV infection in many patients
[18], the efficacious antiviral treatments used in CHB in the last
20 years have prevented in over 90% of cases the progression of
CHB to terminal disease [19], drastically reducing the need for liver
transplantation. Consonant with this conclusion, in the last decade
62.3% of the HDV patients were transplanted for liver failure and
37.7% for hepatocellular carcinoma while only 29.5% of the HBV
patients were transplanted for liver failure and 70.5% were trans-
planted for a hepatocellular carcinoma, the development of which
was not prevented by antiviral therapy.
In conclusion, though the HDV is vanishing in indigenous Ital-
ians, chronic HDV disease still outlives in a cohort of ageing domes-
tic cirrhotics and maintains an impact on liver transplantation
programs. The residual tail of HDV infections is bound to sponta-
neously extinguish in a generation time, yet with a mean age of
58 years, it will remain a medical issue for years to come.
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